

HEPATITIS C VIRUS TREATMENT GUIDELINES (Part 1 of 2)

Treatment naive		Peg-IFN/ribavirin treatment experienced	
Without cirrhosis	With compensated cirrhosis	Without cirrhosis	With compensated cirrhosis
GENOTYPE 1A			
Recommended			
<ul style="list-style-type: none"> • Zepatier for 12wks¹ OR • Mavyret for 8wks OR • Harvoni for 12wks² OR • Eplusa for 12wks 	<ul style="list-style-type: none"> • Zepatier for 12wks¹ OR • Mavyret for 8wks⁵ OR • Harvoni for 12wks OR • Eplusa for 12wks 	<ul style="list-style-type: none"> • Zepatier for 12wks¹ OR • Mavyret for 8wks OR • Harvoni for 12wks OR • Eplusa for 12wks 	<ul style="list-style-type: none"> • Zepatier for 12wks¹ OR • Eplusa for 12wks OR • Mavyret for 12wks
Alternative			
			<ul style="list-style-type: none"> • Harvoni + ribavirin for 12wks
GENOTYPE 1B			
Recommended			
<ul style="list-style-type: none"> • Zepatier for 12wks⁶ OR • Mavyret for 8wks OR • Harvoni for 12wks² OR • Eplusa for 12wks 	<ul style="list-style-type: none"> • Zepatier for 12wks OR • Mavyret for 8wks⁵ OR • Harvoni for 12wks OR • Eplusa for 12wks 	<ul style="list-style-type: none"> • Zepatier for 12wks OR • Mavyret for 8wks OR • Harvoni for 12wks OR • Eplusa for 12wks 	<ul style="list-style-type: none"> • Zepatier for 12wks OR • Eplusa for 12wks OR • Mavyret for 12wks
Alternative			
			<ul style="list-style-type: none"> • Harvoni + ribavirin for 12wks
GENOTYPE 2			
Recommended			
<ul style="list-style-type: none"> • Mavyret for 8wks OR • Eplusa for 12wks 	<ul style="list-style-type: none"> • Eplusa for 12wks OR • Mavyret for 8wks⁵ 	<ul style="list-style-type: none"> • Mavyret for 8wks OR • Eplusa for 12wks 	<ul style="list-style-type: none"> • Eplusa for 12wks OR • Mavyret for 12wks
GENOTYPE 3			
Recommended			
<ul style="list-style-type: none"> • Mavyret for 8wks OR • Eplusa for 12wks 	<ul style="list-style-type: none"> • Mavyret for 8wks⁵ OR • Eplusa for 12wks³ 	<ul style="list-style-type: none"> • Eplusa for 12wks³ 	<ul style="list-style-type: none"> • Mavyret for 16wks OR • Vosevi for 12wks
Alternative			
	<ul style="list-style-type: none"> • Eplusa + ribavirin for 12wks³ • Vosevi for 12wks³ 	<ul style="list-style-type: none"> • Mavyret for 16wks OR • Vosevi for 12wks³ 	<ul style="list-style-type: none"> • Zepatier + Sovaldi for 12wks • Eplusa + ribavirin for 12wks
GENOTYPE 4			
Recommended			
<ul style="list-style-type: none"> • Mavyret for 8wks OR • Eplusa for 12wks OR • Zepatier for 12wks OR • Harvoni for 12wks⁷ 	<ul style="list-style-type: none"> • Eplusa for 12wks OR • Mavyret for 8wks⁵ OR • Zepatier for 12wks OR • Harvoni for 12wks 	<ul style="list-style-type: none"> • Eplusa for 12wks OR • Mavyret for 8wks OR • Zepatier for 12wks⁴ OR • Harvoni for 12wks 	<ul style="list-style-type: none"> • Eplusa for 12wks OR • Zepatier for 12wks⁴ OR • Mavyret for 12wks
Alternative			
			<ul style="list-style-type: none"> • Harvoni + ribavirin for 12wks
GENOTYPE 5, 6			
Recommended			
<ul style="list-style-type: none"> • Mavyret for 8wks⁵ OR • Eplusa for 12wks OR • Harvoni for 12wks⁸ 	<ul style="list-style-type: none"> • Mavyret for 8wks⁵ OR • Eplusa for 12wks OR • Harvoni for 12wks⁸ 	<ul style="list-style-type: none"> • Mavyret for 8wks OR • Harvoni for 12wks OR • Eplusa for 12wks 	<ul style="list-style-type: none"> • Mavyret for 12wks OR • Harvoni for 12wks OR • Eplusa for 12wks

(continued)

PHARMACOLOGICAL THERAPIES

Generic	Brand	Strength	Form	Dosage
elbasvir/grazoprevir	Zepatier	50mg/100mg	tabs	≥ 18yrs : 1 tab once daily.
glecaprevir/pibrentasvir	Mavyret	100mg/40mg	tabs	≥ 12yrs or ≥45kg : 3 tabs once daily with food.
ledipasvir/sofosbuvir	Harvoni	45mg/200mg, 90mg/400mg	tabs	≥ 3yrs (<17kg): 33.75mg/150mg (pellets) once daily; (17–<35kg): 45mg/200mg (tabs or pellets) once daily; (≥35kg): 90mg/400mg (tabs or pellets) once daily. ≥ 18yrs : 90mg/400mg (tabs) once daily.
	Harvoni Oral Pellets	33.75mg/150mg, 45mg/200mg	pellets	
ribavirin	—	200mg, 400mg, 500mg, 600mg	tabs	Take with food in 2 divided doses. ≥ 5yrs (23–33kg): 400mg/day; (34–46kg): 600mg/day; (47–59kg): 800mg/day; (60–74kg): 1g/day; (≥75kg): 1.2g/day. ≥ 18yrs (<75kg): 1g/day; (≥75kg): 1.2g/day.
sofosbuvir	Sovaldi	200mg, 400mg	tabs	≥ 3yrs (<17kg): 150mg (pellets) once daily; (17–<35kg): 200mg (tabs or pellets) once daily; (≥35kg): 400mg (tabs or pellets) once daily. ≥ 18yrs : 400mg (tabs) once daily.
	Sovaldi Oral Pellets	150mg, 200mg	pellets	
sofosbuvir/velpatasvir	Epclusa	200mg/50mg, 400mg/100mg	tabs	≥ 6yrs (17–<30kg): 200mg/50mg once daily; (≥30kg): 400mg/100mg once daily. ≥ 18yrs : 400mg/100mg once daily.
sofosbuvir/velpatasvir/voxilaprevir	Vosevi	400mg/100mg/100mg	tabs	≥ 18yrs : 1 tab once daily with food

NOTES

For recommended and alternative regimens for specific patient populations (eg, treatment-experienced patients previously treated with regimens other than PEG-IFN/ribavirin, decompensated cirrhosis, HIV/HCV co-infection, renal impairment, etc), refer to the full guideline or drug manufacturer's labeling.

- Patients with no baseline NS5A RASs for elbasvir detected. Includes G1a substitutions at amino acid positions 28, 30, 31, or 93 known to confer antiviral resistance.
- An 8-week duration is recommended for treatment-naïve patients without cirrhosis who are HIV uninfected, and whose HCV RNA level is <6 million IU/ml.
- Baseline NS5A RAS Y93H testing for velpatasvir is recommended. If present, ribavirin should be added to the regimen, or change regimen to Vosevi.
- 12 weeks is recommended for patients who experience virologic relapse after PEG-IFN/ribavirin therapy. If the type of prior treatment failure (relapse vs breakthrough/nonresponse) is unknown, another recommended regimen should be used.
- Duration of 12 weeks is recommended for HIV/HCV co-infection.
- Consider an 8-week regimen in patients with genotype 1b and mild fibrosis.
- Consider an 8-week regimen in patients with favorable baseline characteristics (eg, no cirrhosis, HCV RNA <6 million IU/mL, absence of genotype 4r).
- Not recommended for genotype 6e if subtype is known.

REFERENCES

AASLD-IDSA. HCV Guidance: Recommendations for testing, managing, and treating hepatitis C. <http://www.hcvguidelines.org>. Accessed October 20, 2020.